Tuberculosis Elimination and Laboratory Cooperative Agreement

CDC announces available Fiscal Year (FY) 2025 funds to complement tuberculosis (TB) prevention and control activities and laboratory services at state and local levels to reduce TB morbidity and mortality. The goal of this funding is to prevent transmission of M. tuberculosis (TB) and prevent progression from latent TB infection to active TB disease. Funding levels are determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data. Strategies and activities include diagnosis/treatment of persons with TB disease and persons with latent TB infection (LTBI); examination of immigrants and refugees who have an overseas B classification for TB; targeted testing for, and treatment of, LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening. Expected outcomes include (but are not limited to) decreases in TB incidence; increases in patients completing treatment within 12 months; increases in HIV and drug susceptibility testing in TB cases; increases in LTBI testing and treatment completion rates of those recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing and implementation of TB elimination plans.